series-c-plus
Stage
1
Investors
About
MeiraGTx is a clinical-stage genetic medicine company developing AAV-based gene therapies and enabling technologies, including a riboswitch gene regulation platform and an end-to-end GMP manufacturing ecosystem, to treat inherited and non-inherited diseases (programs include xerostomia, retinal dystrophies and Parkinson’s disease).
Explore MeiraGTx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.